Genscript Biotech Stock Probability of Future Pink Sheet Price Finishing Over 1.34
| GNNSF Stock | USD 1.26 0.00 0.00% |
Genscript |
Genscript Biotech Target Price Odds to finish over 1.34
The tendency of Genscript Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 1.34 or more in 90 days |
| 1.26 | 90 days | 1.34 | about 81.76 |
Based on a normal probability distribution, the odds of Genscript Biotech to move over $ 1.34 or more in 90 days from now is about 81.76 (This Genscript Biotech probability density function shows the probability of Genscript Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Genscript Biotech price to stay between its current price of $ 1.26 and $ 1.34 at the end of the 90-day period is about 16.51 .
Assuming the 90 days horizon Genscript Biotech has a beta of -0.0319. This usually indicates as returns on the benchmark increase, returns on holding Genscript Biotech are expected to decrease at a much lower rate. During a bear market, however, Genscript Biotech is likely to outperform the market. Additionally Genscript Biotech has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Genscript Biotech Price Density |
| Price |
Predictive Modules for Genscript Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Genscript Biotech. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Genscript Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Genscript Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Genscript Biotech is not an exception. The market had few large corrections towards the Genscript Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Genscript Biotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Genscript Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.16 | |
β | Beta against Dow Jones | -0.03 | |
σ | Overall volatility | 0.07 | |
Ir | Information ratio | -0.13 |
Genscript Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Genscript Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Genscript Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Genscript Biotech generated a negative expected return over the last 90 days | |
| Genscript Biotech may become a speculative penny stock | |
| The company reported the revenue of 510.6 M. Net Loss for the year was (347.87 M) with profit before overhead, payroll, taxes, and interest of 303.48 M. | |
| Genscript Biotech has accumulated about 1.26 B in cash with (136.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Roughly 38.0% of the company shares are held by company insiders |
Genscript Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Genscript Pink Sheet often depends not only on the future outlook of the current and potential Genscript Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Genscript Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.1 B |
Genscript Biotech Technical Analysis
Genscript Biotech's future price can be derived by breaking down and analyzing its technical indicators over time. Genscript Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Genscript Biotech. In general, you should focus on analyzing Genscript Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Genscript Biotech Predictive Forecast Models
Genscript Biotech's time-series forecasting models is one of many Genscript Biotech's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Genscript Biotech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Genscript Biotech
Checking the ongoing alerts about Genscript Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Genscript Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Genscript Biotech generated a negative expected return over the last 90 days | |
| Genscript Biotech may become a speculative penny stock | |
| The company reported the revenue of 510.6 M. Net Loss for the year was (347.87 M) with profit before overhead, payroll, taxes, and interest of 303.48 M. | |
| Genscript Biotech has accumulated about 1.26 B in cash with (136.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Roughly 38.0% of the company shares are held by company insiders |
Other Information on Investing in Genscript Pink Sheet
Genscript Biotech financial ratios help investors to determine whether Genscript Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genscript with respect to the benefits of owning Genscript Biotech security.